FibroBiologics will present at Bio-Europe 2025 on November 4, highlighting their innovations in chronic disease therapeutics.
Quiver AI Summary
FibroBiologics, Inc., a biotechnology company based in Houston, announced that its CEO Pete O’Heeron will present at the Bio-Europe 2025 conference in Vienna, Austria, scheduled for November 3-5, 2025. The company will give a presentation on November 4 at 4:15 p.m. CET and will be available for one-on-one meetings with investors during the event. FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases utilizing fibroblast cells, holding over 270 patents related to various medical applications including wound healing and cancer. For more details, interested parties can visit their website or contact them via email.
Potential Positives
- FibroBiologics is set to present at the Bio-Europe 2025 conference, indicating active engagement in industry events and opportunities for networking and exposure to potential investors and collaborators.
- The company holds over 270 patents, highlighting its strong intellectual property portfolio, which can enhance its competitive position in the biotechnology sector.
- The focus on developing treatments for a variety of chronic diseases demonstrates a broad and potentially impactful therapeutic pipeline, which may attract interest from investors and partners.
- The engagement in discussions about next-generation medical advancements positions FibroBiologics as a forward-thinking player in the field of cell therapy and tissue regeneration.
Potential Negatives
- None
FAQ
What is FibroBiologics focused on developing?
FibroBiologics is focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials.
When will FibroBiologics present at Bio-Europe 2025?
FibroBiologics will present at Bio-Europe 2025 on November 4, 2025, at 4:15 p.m. CET.
Where is the Bio-Europe 2025 conference taking place?
The Bio-Europe 2025 conference is taking place at the Vienna Congress and Convention Center in Vienna, Austria.
How can I contact FibroBiologics for more information?
You can contact FibroBiologics via email at [email protected] for more information.
What types of patents does FibroBiologics hold?
FibroBiologics holds over 270 US and international patents related to various clinical pathways, including cancer and wound healing.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FBLG Insider Trading Activity
$FBLG insiders have traded $FBLG stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $FBLG stock by insiders over the last 6 months:
- HAMID KHOJA (Chief Scientific Officer) purchased 20,000 shares for an estimated $16,800
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$FBLG Hedge Fund Activity
We have seen 25 institutional investors add shares of $FBLG stock to their portfolio, and 43 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 1,014,732 shares (-57.5%) from their portfolio in Q2 2025, for an estimated $631,366
- MILLENNIUM MANAGEMENT LLC added 480,645 shares (+inf%) to their portfolio in Q2 2025, for an estimated $299,057
- STATE STREET CORP removed 450,952 shares (-79.6%) from their portfolio in Q2 2025, for an estimated $280,582
- GEODE CAPITAL MANAGEMENT, LLC removed 325,691 shares (-53.0%) from their portfolio in Q2 2025, for an estimated $202,644
- VANGUARD GROUP INC removed 186,638 shares (-13.1%) from their portfolio in Q2 2025, for an estimated $116,126
- CITADEL ADVISORS LLC added 185,144 shares (+383.9%) to their portfolio in Q2 2025, for an estimated $115,196
- NORTHERN TRUST CORP removed 158,003 shares (-76.7%) from their portfolio in Q2 2025, for an estimated $98,309
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$FBLG Analyst Ratings
Wall Street analysts have issued reports on $FBLG in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 09/10/2025
- HC Wainwright & Co. issued a "Buy" rating on 08/05/2025
To track analyst ratings and price targets for $FBLG, check out Quiver Quantitative's $FBLG forecast page.
$FBLG Price Targets
Multiple analysts have issued price targets for $FBLG recently. We have seen 2 analysts offer price targets for $FBLG in the last 6 months, with a median target of $13.0.
Here are some recent targets:
- Matthew Caufield from HC Wainwright & Co. set a target price of $10.0 on 09/12/2025
- Jason Kolbert from D. Boral Capital set a target price of $16.0 on 09/10/2025
Full Release
HOUSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the Bio-Europe 2025 conference taking place November 3-5, 2025, at the Vienna Congress and Convention Center in Vienna, Austria.
FibroBiologics will deliver a company presentation at 4:15 p.m. CET on Tuesday, November 4, and will be available for one-on-one investor meetings throughout the event.
For more information, please visit FibroBiologics' website or email FibroBiologics at: [email protected] .
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com .
General Inquiries:
[email protected]
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
[email protected]
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
[email protected]
